300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Czech Republic
Marshall Islands
Kuwait
Luxembourg
Malta
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Mozambique
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Morocco
Kazakhstan
Cayman Islands
Venezuela
Guatemala
Uganda
Myanmar
Turkey
Uruguay
Moldova
Paraguay
Seychelles
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Jan Møller Mikkelsen, Co-Founder, President and CEO at Ascendis Pharma

Jan Møller Mikkelsen

Co-Founder, President and CEO @ Ascendis Pharma

Esbjerg, Denmark

Jan Møller Mikkelsen is a Series A investor at Ascendis Pharma in Esbjerg focused on Life Science and Biotechnology. Jan Møller Mikkelsen - Deputy Director @ Skattestyrelsen

Total investments:
2
Last investment:
Lead investor:
50%

Last updated:

Industries Jan Møller Mikkelsen invests in

Life ScienceBiotechnologyPharmaceutical

Stages Jan Møller Mikkelsen invests in

Series ASeries B

Countries Jan Møller Mikkelsen invests in

China

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Life Science 1 (50%)
  • Biotechnology 1 (50%)
  • Pharmaceutical 1 (50%)

Stage

  • Series A 1 (50%)
  • Series B 1 (50%)

Investments

CompanyDescriptionRoundLinks
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. $150M / Series B / Jan 08, 2021
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. $40M / Series A / Nov 13, 2018

Co-Investors

Ascendis Pharma

About Ascendis Pharma

VC Fund · Palo Alto, United States

Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugsof proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.

Ascendis Pharma Contacts

NameEmailPhoneSocials
Birgitte Volck
Birgitte Volck Non Executive Director
Harald Rau Senior Vice President, Chief Scientific Officer
Jan Møller Mikkelsen
Jan Møller Mikkelsen Co-Founder, President and CEO
Lotte Sønderbjerg
Lotte Sønderbjerg SVP Chief Administrative Offer Managing Director Ascendis GmbH
Michael Beckert Chief Medical Officer (acting)

Sign up to unlock verified contacts

Unlock Contacts

See all 7 contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Czech Republic
Marshall Islands
Kuwait
Luxembourg
Malta
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Mozambique
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Morocco
Kazakhstan
Cayman Islands
Venezuela
Guatemala
Uganda
Myanmar
Turkey
Uruguay
Moldova
Paraguay
Seychelles
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Jan Møller Mikkelsen invest in?

Jan Møller Mikkelsen invests primarily in Life Science, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Jan Møller Mikkelsen?

Public channels for Jan Møller Mikkelsen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Jan Møller Mikkelsen last invest?

The most recent investment recorded for Jan Møller Mikkelsen closed in Jan 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Jan Møller Mikkelsen Jan Møller Mikkelsen Find email